CORT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CORT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Corcept Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $37.9 Mil. Corcept Therapeutics's Revenue for the three months ended in Dec. 2023 was $135.4 Mil. Hence, Corcept Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 25.52.
The historical rank and industry rank for Corcept Therapeutics's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Corcept Therapeutics's highest Days Sales Outstanding was 36.09. The lowest was 22.34. And the median was 27.08.
Corcept Therapeutics's Days Sales Outstanding declined from Dec. 2022 (26.77) to Dec. 2023 (25.52).
The historical data trend for Corcept Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 22.34 | 23.79 | 26.84 | 26.65 | 27.31 |
Corcept Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 26.77 | 27.47 | 25.24 | 24.80 | 25.52 |
For the Biotechnology subindustry, Corcept Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Corcept Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as
Days Sales Outstanding (A: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2022 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (31.057 | + | 41.123) | / | 2 ) | / | 482.375 | * | 365 |
= | 36.09 | / | 482.375 | * | 365 | ||||
= | 27.31 |
Corcept Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:
Days Sales Outstanding (Q: Dec. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Sep. 2023 ) | + | Accounts Receivable (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) | * | Days in Period |
= | ( (34.626 | + | 41.123) | / | 2 ) | / | 135.405 | * | 365 / 4 |
= | 37.8745 | / | 135.405 | * | 365 / 4 | ||||
= | 25.52 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (NAS:CORT) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Corcept Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Swisher Daniel N Jr | director | C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080 |
William Guyer | officer: Chief Development Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Gary Charles Robb | officer: CHIEF FINANCIAL OFFICER | C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Joseph Douglas Lyon | officer: Chief Accounting Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Sean Maduck | officer: See Remarks | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
David L Mahoney | director | SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014 |
Hazel Hunt | officer: Chief Scientific Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Joseph K Belanoff | director, officer: CHIEF EXECUTIVE OFFICER | 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Baker G Leonard Jr | director, 10 percent owner | 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005 |
Joshua M. Murray | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Atabak Mokari | officer: Chief Financial Officer | 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043 |
Gillian Cannon | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Gregg H Alton | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Kimberly Park | director | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
Andreas Grauer | officer: Chief Medical Officer | C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025 |
From GuruFocus
By sperokesalga sperokesalga • 04-26-2023
By GuruFocus Research • 09-07-2023
By Marketwired • 11-01-2023
By Marketwired • 07-26-2023
By PRNewswire • 01-02-2024
By Business Wire Business Wire • 12-15-2022
By Tiesvg Tiesvg • 12-29-2022
By PurpleRose PurpleRose • 07-27-2022
By Value_Insider Value_Insider • 10-27-2022
By GuruFocus Research • 09-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.